29 May 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Hong Kong-based OrbusNeich has launched dual therapy stent to address the challenges of delayed healing of the coronary artery associated with monotherapy drug eluting stents (DES), which is the current standard-of-care for the treatment of coronary artery disease (CAD).
Combo Dual Therapy Stent is designed to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of OrbusNeich's proven pro-healing technology. The stent also uses an abluminal sirolimus drug elution that is delivered from a biodegradable polymer, which achieves full and complete dissipation by 90 days.
"The Combo Dual Therapy Stent is the next wave of drug eluting stent technology," said Mr Al Novak, OrbusNeich's chairman and CEO. "The dual therapy approach maintains the efficacy of monotherapy drug eluting stents while providing the benefits of accelerated stent endothelialization and healing. With CE Mark approval, the Combo Dual Therapy Stent has set a new, rigorous standard for stent innovation."
Dr Roxana Mehran, Mount Sinai Medical Center, US, said that, "I believe that Combo is a next-generation drug eluting stent, combining the anti-restenotic property of drug eluting stents with endothelial progenitor cell (EPC) capture, which is able to heal the surface of the stent."
"We're most excited about the possibility of actually having a stent for which you do not need prolonged dual antiplatelet therapy (DAPT), and I think that is the future. Obligatory, prolonged DAPT is no longer going to be the standard, we cannot accept that anymore. And so, we're looking for a safer stent, and I think this very unique and interesting platform has incredible promise," added Dr Mehran.